Improving treatment outcomes by understanding cytogenetics in myelodysplastic

Published: June 10, 2009
Abstract Views: 163
PDF: 324
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Myelodysplastic syndromes (MDS) represent a heterogeneous group of blood disorders that are generally characterised by refractory anaemia (RA) or cytopenia, hypercellular bone marrow, and ineffective haematopoiesis. Most cases of MDS have an increased risk of transformation to acute myeloid leukaemia (AML). The prognosis of patients with MDS varies considerably, reflecting the underlying heterogeneity within this class of disorders.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Supporting Agencies

How to Cite

Giagounidis, A. (2009). Improving treatment outcomes by understanding cytogenetics in myelodysplastic. Hematology Meeting Reports (formerly Haematologica Reports), 2(14). https://doi.org/10.4081/hmr.v2i14.508